Lixte Biotechnology (NASDAQ:LIXT) Announces Quarterly Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) announced its quarterly earnings data on Tuesday. The company reported ($0.34) earnings per share for the quarter, FiscalAI reports.

Lixte Biotechnology Trading Up 2.1%

Shares of NASDAQ LIXT traded up $0.06 during midday trading on Wednesday, hitting $3.13. The company’s stock had a trading volume of 25,671 shares, compared to its average volume of 41,429. The firm has a market capitalization of $23.43 million, a price-to-earnings ratio of -2.66 and a beta of 0.86. Lixte Biotechnology has a one year low of $0.64 and a one year high of $6.26. The stock has a fifty day moving average price of $3.05 and a 200 day moving average price of $3.88.

Institutional Trading of Lixte Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC raised its stake in shares of Lixte Biotechnology by 47.0% in the fourth quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock worth $422,000 after purchasing an additional 34,350 shares during the last quarter. Federation des caisses Desjardins du Quebec boosted its position in shares of Lixte Biotechnology by 83.6% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after buying an additional 42,530 shares during the last quarter. DRW Securities LLC boosted its position in shares of Lixte Biotechnology by 11.6% during the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after buying an additional 5,645 shares during the last quarter. Geode Capital Management LLC increased its holdings in Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after buying an additional 10,722 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Lixte Biotechnology in the 4th quarter worth about $57,000. Institutional investors own 5.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lixte Biotechnology in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.